A RANKL Wrinkle: Denosumab-Induced Hypocalcemia

Phototherapy-induced Hypocalcemia

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis

Hypocalcemia is the most common major adverse event in patients with osteoporosis receiving the bone resorption inhibitor denosumab; however, limited information is available regarding risk factors of hypocalcemia. Therefore, this study aimed to identify the risk factors of hypocalcemia induced by denosumab treatment for osteoporosis. We retrospectively reviewed the records of patients who had ...

Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.

potasio en el colon. El mecanismo a través del cual se aumenta la secreción colónica de potasio en estos pacientes es complejo; y depende de varios factores. Por un lado, existe un aumento de la actividad de la bomba Na+/K+ ATPasa en la membrana basolateral de la célula intestinal, que conlleva a un aumento de la concentración de potasio intracelular y a un aumento en la conductividad del potas...

Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer

Denosumab is a monoclonal antibody used for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Hypocalcemia is a rare and dangerous side effect of the drug Denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcemia after the administration of the drug. The patient's vitamin D levels were low when chec...

Identification of the risk factors associated with hypocalcemia induced by denosumab.

Denosumab, a fully human monoclonal antibody that inhibits the receptor activator of nuclear factor-κB ligand, inhibits the activation of osteoclasts. Some clinical trials have shown that denosumab suppresses bone resorption in patients with advanced cancer, but hypocalcemia has been reported as a serious adverse effect after the administration of denosumab. It is difficult to predict hypocalce...